衛星演講 Satellite Speech

Peripheral T-cell Receptor Repertoire as a Prognostic Biomarker and Indicator of Treatment Response in Breast Cancer

Exploring Novel Precision Strategies Involving ADCs for the Treatment of Platinum-Resistant Ovarian Cancer

New Frontiers in Advanced Ovarian Cancer: From First-Line Standards to Recurrence and Emerging Therapies

Reprogramming the CD47–SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering

The Evolving Landscape of BRAF-Targeted Therapy in CRC and Melanoma

The Integration of Next Generation Sequencing and Proteomics Precision Cancer Care

Treatment Considerations in BRAF-Mutant NSCLC: New Solution and Future Directions

Current and Future Management of HER2 mutant NSCLC

The effective combination therapy for unresectable or metastatic UC patient

From Registry to Therapy: Taiwan epNEC Experience and the Potential of DLL3 in Treatment

Evolving Role of Third Generation EGFR TKIs in EGFR Mutated NSCLC - Emerging Solutions

Evolving Standards in metastatic EGFRm NSCLC: Real-world Insights and Implementation of TKI-Chemotherapy Combinations

Integrating pembrolizumab into standard of care for LA HNSCC

Clinical Decision-making in EGFR-mutant NSCLC: Navigating First-line Treatment in Real-world Practice

Navigating the Post-CDK4/6i Landscape: A Biomarker-Driven Approach to HR+ mBC

Just-Right Therapy: Building Durable Control in Challenging NSCLC

Rethinking Long-term Survival in EGFR-mutant NSCLC: From First-line Strategy to Sequential Treatment Planning

From Biomarkers to First‑Line Regimens: Precision‑Guided Treatment in Advanced GI Cancers

Opening Remarks

A New Standard of Care: How Jemperli Improves Outcomes for Patients with Primary Advanced or Recurrent Endometrial Cancer

Discussion

Advancing 3L+ mCRC Care: Clinical Evidence and Real-World Insights of Fruzaqla

Turning Tumor Shrinkage into Symptom Relief: Immunotherapy in Esophageal and Gastric Cancer

Discussion

Closing Remarks

The upfront management strategy of Advanced Prostate Cancer

Optimizing the treatment sequence in HR+/HER2- mBC after ET resistance, focusing on the PI3K AKT mTOR pathway

Welcome & Introduction

Positioning Trodelvy in the Treatment Sequence: Insights from Second-Line Real-World Evidence and First-Line data

The Value of Liquid Biopsy & Multi-Omics Across All Stages of Cancer Care: Pan-Cancer Perspectives

Q&A

AI-Powered Multi-Omic ctDNA for Multi-Cancer Early Detection: Scalable Cancer Screening with SPOT-MAS

Q&A

Liquid Biopsy Applications in Gastrointestinal & Colorectal Cancers: Case-Based Insights on Profiling & Monitoring Current Practice & Future Directions

Q&A

Clinical Integration of Liquid Biopsy in Breast Cancer and Sarcoma: Current Practice & Future Directions

Q&A

Advanced AI-Driven Biomarkers & Liquid Biopsy Integration in Precision Oncology: Asia-Pacific Insights

Q&A

Panel Discussion & Interactive Q&A + Closing Remarks